Amundi’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Amundi’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-600,815	Closed	-$69.9M	–	2114
2023 Q3	$69.9M	Buy	600,815 +213,350	+55%	+$22.9M	0.03%	427
2023 Q2	$39.9M	Buy	387,465 +93,064	+32%	+$9.82M	0.02%	565
2023 Q1	$31.8M	Buy	294,401 +10,052	+4%	+$1.11M	0.02%	610
2022 Q4	$32.2M	Buy	284,349 +7,734	+3%	+$642K	0.02%	595
2022 Q3	$18.5M	Buy	276,615 +125,012	+82%	+$8.73M	0.01%	709
2022 Q2	$12M	Sell	151,603 -12,531	-8%	-$1.19M	0.01%	732
2022 Q1	$18.4M	Sell	164,134 -10,871	-6%	-$1.06M	0.01%	691
2021 Q4	$15.8M	Sell	175,005 -16,573	-9%	-$1.81M	0.01%	739
2021 Q3	$21M	Sell	191,578 -25,667	-12%	-$2.66M	0.01%	676
2021 Q2	$20.3M	Buy	+217,245	New	+$20M	0.01%	675

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Blue Trust Inc Alpharetta, Georgia $9.51B AUM 13.02% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.22B AUM 22.8% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Amundi's HZNP Position: Q4 2023 in Review

Amundi sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 600,815 shares — an estimated $69.9M sold.

Amundi first reported a position in HZNP in Q2 2021 and held it in 10 quarters. The position peaked at $69.9M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Amundi reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Amundi sold 600,815 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $69.9M.
Amundi first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2021 and held it in 10 quarters.
Amundi's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $69.9M in Q3 2023.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Amundi's 13F filing for Q4 2023, filed 14 Feb 2024.